Canada Markets open in 9 hrs 20 mins

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2520-0.0010 (-0.40%)
At close: 03:59PM EST
Sign in to post a message.
  • F
    Freedom
    TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
    A total of 701 subjects have been dosed to date in the Study. The Company, in collaboration with Delta Health, has initiated the enrollment activities in Turkey at MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 research sites and over 6000 in-patient hospital beds.

    The Study’s expansion into Turkey complements the Company’s global commercialization plan for Bucillamine as a potential treatment for mild to moderate COVID-19. As previously reported, in light of Phase 3 clinical studies and FDA approvals of oral antiviral treatments by Pfizer and Merck, it was evident that to improve the Study’s outcome, a diversified patient population from different countries is important to support future global regulatory submissions. In addition, a diversified subject population supports ongoing discussions with pharmaceutical companies in Turkey and international markets.
    The Company is on-track to complete study enrollment in Q1-2022. Also, the Company is preparing its regulatory package for submission to the FDA and international regulatory authorities for drug approvals thereafter.
    Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study and we are focused on completing enrollment, preparing the regulatory packages for the FDA and international health authorities, and negotiating manufacturing and marketing agreements with pharmaceutical companies for commercialization.”

    The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
  • I
    IDK
    Morningstar has RVV fair valued at 1.13, but this just a reference, it also showing the value may drop to 2 cent

    Valuation as of 19 Jan 2022
    Fair ValueQoant
    1.13
    UncertaintyQoant:
    Extreme
    Last Close
    0.32
    RVV is Under
    Valued at a 72%
    discount.
    Economic Moat
    None
    Financial Health
    Moderate
    1-Star Price
    79.13
    5-Star Price
    0.02
  • B
    Bucci Man
    Morningstar has Rvvtf valued at .89 fair value, time to buy.
  • C
    Crusader
    💊"We are now in the final stages in our Phase 3 study and we are focused on completing enrollment, preparing the regulatory packages for the FDA and international health authorities, and negotiating manufacturing and marketing agreements with pharmaceutical companies for commercialization.”

    --Michael Frank, CEO Revive Therapeutics 🎯💪
  • M
    M - good M
    yesterday's update was great because 1 it confirms that we reached 700+ patients and 2 because it says that they are already starting to enroll patients in turkey. previously, rvv said they expected to start in mid February. so before saying it's the same news as before make sure you know that you're taking about
  • a
    andrew
    SP dropping because everyone is rushing results , and are to impatient so they ate giving up hope .. if the company was failing they would not be expanding .. good things take time .. everyone is so quick to judge and bash because they are not the ones running the company they are expecting a quick pay out ..
    nobody sold a large amount of shares .. expanding spending more money.. good news to me
  • C
    Crusader
    🎯 "The Company is on-track to complete study enrollment in Q1-2022. Also, the Company is preparing its regulatory package for submission to the FDA and international regulatory authorities for drug approvals thereafter."
  • C
    Crusader
    Nice close up 16% on Canadian side today. looks like the market liked the News 🍻
  • S
    Schlumdog
    I had a dream this shot up to $240. Let’s see if I have the gift of foresight
  • d
    damien
    Red monday???
  • W
    WickedEV
    miss ambiguous sure quiet this morning … she must be buying too. Good girl
  • I
    InTheBank
    Poor Missnotsoambitious after all. I cant wait to see your next comment. I think your shorter employer wont pay you for a while, he’s broke.
  • K
    Katandra Millosh
    I'd like to be wrong and hate to be pessimistic, but current market conditions make me believe we are in for a bumpy ride (at least until completion of the trial).
  • M
    M - good M
    Clinical trial webpage updated today. Date changes (as we already knew) and dosage now chosen to be 600mg. All good. Let's go.
  • R
    Rudolph
    Bought more. Holidays’ expenses taken care of so back to adding more shares. Again, the stock price has decoupled from the company… it happens.
  • M
    Mike
    Nice! Big buys coming in at close!
  • D
    Dino
    Nice positive news!
  • F
    Freedom
    Its very simple..look at the BIG PICTURE and take this opportunity...buy more @ Bargain-basement prices. It's a gift! ..Buci 🔥